I guess we agree that the negligible systemic absorption is likely to be a huge plus in treatment of IBD where PDE4 inhibitors, like Otezla, have stumbled on dose limiting systemic adverse effects.
(0)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
